Suppr超能文献

来自角膜溃疡临床试验的丝状真菌分离株的体外药敏试验。

In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.

机构信息

Aravind Eye Care System, Madurai, India.

F.I. Proctor Foundation, University of California San Francisco, San Francisco, California.

出版信息

Am J Ophthalmol. 2014 Feb;157(2):318-26. doi: 10.1016/j.ajo.2013.10.004. Epub 2013 Oct 22.

Abstract

PURPOSE

To describe the minimum inhibitory concentration (MIC) of fungal isolates to natamycin and voriconazole, and to compare these MICs to previous ocular susceptibility studies.

DESIGN

Experimental laboratory study using isolates from a randomized clinical trial.

METHODS

The Mycotic Ulcer Treatment Trial I was a randomized, double-masked, multicenter trial comparing topical natamycin and voriconazole for fungal keratitis treatment. Susceptibility testing to natamycin and voriconazole were performed according to Clinical and Laboratory Standards Institute methods. The relationship between organism and MIC was assessed. A literature review was performed to compare results to previous ocular susceptibility studies.

RESULTS

Of the 323 patients enrolled in the trial, MICs were available for 221 (68%). Fusarium (n = 126) and Aspergillus species (n = 52) were the most commonly isolated organisms. MICs to natamycin and voriconazole were significantly different across all genera (P < .001). The MIC median (MIC50) and 90th percentile (MIC90) for natamycin were equal to or higher than voriconazole for all organisms except Curvularia species. Compared to other organisms, Fusarium species isolates had the highest MICs to voriconazole and Aspergillus flavus isolates had the highest MICs to natamycin. Our results were similar to previous reports except that the voriconazole MIC90 against Aspergillus species was 2-fold higher and the natamycin MIC90 against Aspergillus fumigatus was 4-fold higher in our study.

CONCLUSION

In this large susceptibility study, Fusarium isolates were least susceptible to voriconazole and A flavus isolates were least susceptible to natamycin when compared to other filamentous fungi. In the future, susceptibility testing may help guide therapy if performed in a timely manner.

摘要

目的

描述真菌分离物对那他霉素和伏立康唑的最小抑菌浓度(MIC),并将这些 MIC 与之前的眼部药敏研究进行比较。

设计

使用随机临床试验中的分离物进行的实验性实验室研究。

方法

真菌性溃疡治疗试验 I 是一项随机、双盲、多中心试验,比较了局部那他霉素和伏立康唑治疗真菌性角膜炎的效果。根据临床和实验室标准协会的方法进行了那他霉素和伏立康唑的药敏试验。评估了生物体与 MIC 的关系。进行了文献回顾,将结果与之前的眼部药敏研究进行比较。

结果

在试验中纳入的 323 例患者中,有 221 例(68%)可获得 MIC 值。镰孢菌(n = 126)和曲霉属(n = 52)是最常见的分离物。所有属的那他霉素和伏立康唑 MIC 均有显著差异(P <.001)。除弯孢菌属外,所有生物体的那他霉素 MIC 中位数(MIC50)和 90 百分位数(MIC90)均等于或高于伏立康唑。与其他生物体相比,镰孢菌属分离物对伏立康唑的 MIC 最高,而黄曲霉属分离物对那他霉素的 MIC 最高。除了本研究中对曲霉属的伏立康唑 MIC90 是之前报道的 2 倍,以及对烟曲霉的那他霉素 MIC90 是之前报道的 4 倍之外,我们的结果与之前的报告相似。

结论

在这项大型药敏研究中,与其他丝状真菌相比,镰孢菌属分离物对伏立康唑的敏感性最低,而 A. flavus 分离物对那他霉素的敏感性最低。如果及时进行药敏试验,未来它可能有助于指导治疗。

相似文献

1
In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.
Am J Ophthalmol. 2014 Feb;157(2):318-26. doi: 10.1016/j.ajo.2013.10.004. Epub 2013 Oct 22.
2
3
Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Arch Ophthalmol. 2007 Jun;125(6):789-93. doi: 10.1001/archopht.125.6.789.
5
The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole.
JAMA Ophthalmol. 2013 Apr;131(4):422-9. doi: 10.1001/jamaophthalmol.2013.1497.
6
Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.
Ophthalmology. 2014 Aug;121(8):1495-500.e1. doi: 10.1016/j.ophtha.2014.03.004. Epub 2014 Apr 16.
7
Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.
JAMA Ophthalmol. 2016 Jun 1;134(6):693-6. doi: 10.1001/jamaophthalmol.2016.0530.
8
Voriconazole versus natamycin as primary treatment in fungal corneal ulcers.
Clin Exp Ophthalmol. 2011 Jul;39(5):434-40. doi: 10.1111/j.1442-9071.2010.02473.x. Epub 2011 Jun 28.
9
Necessity to identify the causative agent for appropriate treatment in fungal corneal ulcer: an in vitro study.
J Mycol Med. 2018 Mar;28(1):201-205. doi: 10.1016/j.mycmed.2017.07.009. Epub 2018 Feb 2.

引用本文的文献

1
Association between in vitro susceptibility and clinical outcomes in fungal keratitis.
J Ophthalmic Inflamm Infect. 2024 Sep 2;14(1):42. doi: 10.1186/s12348-024-00418-w.
2
Pathogenicity is associated with population structure in a fungal pathogen of humans.
bioRxiv. 2024 Jul 10:2024.07.05.602241. doi: 10.1101/2024.07.05.602241.
3
Rapid Point-of-Care Identification of Aspergillus Species in Microbial Keratitis.
JAMA Ophthalmol. 2023 Oct 1;141(10):966-973. doi: 10.1001/jamaophthalmol.2023.4214.
4
Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom.
Eye (Lond). 2024 Feb;38(3):529-536. doi: 10.1038/s41433-023-02719-1. Epub 2023 Sep 8.
8
Drug reservoir function of voriconazole impregnated human amniotic membrane: An study.
Indian J Ophthalmol. 2021 May;69(5):1068-1072. doi: 10.4103/ijo.IJO_2649_20.

本文引用的文献

1
The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole.
JAMA Ophthalmol. 2013 Apr;131(4):422-9. doi: 10.1001/jamaophthalmol.2013.1497.
3
EUCAST technical note on voriconazole and Aspergillus spp.
Clin Microbiol Infect. 2013 Jun;19(6):E278-80. doi: 10.1111/1469-0691.12148. Epub 2013 Feb 15.
4
Fusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes.
Cornea. 2013 May;32(5):667-73. doi: 10.1097/ICO.0b013e318277ac74.
5
Natamycin and voriconazole in Fusarium and Aspergillus keratitis: subgroup analysis of a randomised controlled trial.
Br J Ophthalmol. 2012 Nov;96(11):1440-1. doi: 10.1136/bjophthalmol-2012-301825. Epub 2012 Aug 21.
6
Successful medical management of recalcitrant Fusarium solani keratitis: molecular identification and susceptibility patterns.
Mycopathologia. 2012 Sep;174(3):233-7. doi: 10.1007/s11046-012-9542-y. Epub 2012 Apr 15.
8
10
Resistant Fusarium keratitis progressing to endophthalmitis.
Eye Contact Lens. 2012 Sep;38(5):331-5. doi: 10.1097/ICL.0b013e318235c5af.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验